Liver Disease — Pipeline

The premise

The mechanism we're betting on.

NAFLD/NASH-focused with fibrosis-regression endpoint. Cross-walks with the atherosclerosis reversal layer-3 mechanism (mineral resorption / macrophage axis) — both indications share the same proposed novel pathway. The full mechanism map — including compound list, dose escalation, pre-specified biomarker thresholds, and the cross-walk modifiers used when re-fitting blends from related indications — is part of the gated methodology pack.Gated

RWE — real-world public landscape

What the rest of the world is doing.

Numbers below are surfaced by Atlas Bio's ClinicalTrials.gov and PubMed RWE pipelines, run against the Liver Disease indication. Counts are industry-wide trials registered on ClinicalTrials.gov, not Atlas Bio studies. Methodology →

RWE refreshed 2026-05-12

Phase I (B1/B2)

197

trials

Phase II (B3)

211

trials

Phase III (B4)

100

trials

Phase IV (B5)

trials

Top public trials by enrollment

NCT07165028 · A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) · Eli Lilly and Company · n=4,500 · PHASE3 · RECRUITING

NCT02548351 · Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment · Intercept Pharmaceuticals · n=2,477 · PHASE3 · TERMINATED

NCT01245608 · Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables. · Tehran University of Medical Sciences · n=2,400 · PHASE3 · COMPLETED

Recent published clinical evidence

Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. · PMID 36549296 · Cell metabolism · 2023
Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. · PMID 35860380 · Frontiers in cellular and infection microbiology · 2022
Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients wi · PMID 33838673 · Nutrition journal · 2021

Pre-registered predictions

Locked before readout.

Predictions for this study are SHA-256 locked before any readout. Pre-registration covers target engagement, primary endpoint, secondary endpoints, and the falsification criterion. The hash, prediction wording, and timestamp are available to verified clinicians and indication researchers on request.Gated

Methodology pillars used

Same stack, every indication.

M2 · Pre-Registration — SHA-256 locking before readout.
M1 · IBC Reasoning — 19-agent audit (11 core + 8 reasoning nodes).
M3 · Cross-Trial Validation — mechanism-anchored bridging across indications.
M4 · RWE Pipelines — ClinicalTrials.gov, PubMed, FDA, EDGAR feeds (the source of the numbers above).

Want the full Liver Disease protocol?

The abstract above is open. Compound lists, dose escalations, SHA-256-locked prediction documents, agent-network reasoning chains, and trial design specifics are available to verified clinicians, indication researchers, and sponsors under MNDA. Contact management to begin the access request.

Contact management →